Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC);H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR);S. 2553-Know the Lowest Price Act;Proposed HHS-OIG rule RIN -936-AAO8 under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.;H.R. 6-SUPPORT for Patients and Communities Act relating to S.2460 & H.R. 3528 (Every Prescription Controlled Securely Act);
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) via BROWN RUDNICK LLP
2019 · first_quarter · 1T
The Verifying Accurate Leading-edge IVCT Development Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2019 · first_quarter · 1T
Source: Senate LDA
| AMNEAL PHARMACEUTICALS |
| 21 |
| 2013–2018 |
| NATIONAL ASSOCIATION OF DENTAL PLANS | 20 | 2013–2017 |
| NORWALK HOSPITAL | 18 | 2008–2011 |
| QUALITY DIABETES CARE COALITION | 17 | 2010–2013 |
| VILLAGE HEALTH | 17 | 2007–2011 |
| MIRACA LIFE SCIENCES | 16 | 2012–2016 |
| SURGICAL CARE AFFILIATES | 11 | 2008–2010 |
| EXELA HOLDINGS, LLC | 10 | 2014–2016 |
| ZYDUS PHARMACEUTICALS (USA) INC. | 8 | 2014–2016 |
| HEALTH CARE NAVIGATORS, LLC | 7 | 2011–2012 |
| BOEHRINGER INGELHEIM PHARMACUTICALS INC | 6 | 2007–2008 |
| HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) | 6 | 2018–2019 |
| LUPIN PHARMACEUTICALS INC | 6 | 2017–2018 |
| DEL MONTE FOODS | 5 | 2007–2008 |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 5 | 2009–2010 |
| NEUROSCIENCE CENTERS OF FLORIDA FOUNDATION, INC. | 4 | 2012 |
| GLOBAL VEHICLES USA, INC. | 3 | 2010–2011 |
| AMERICAN GAS ASSOCIATION | 1 | 2008 |
| CARABETTA ENTERPRISES INC | 1 | 2007 |
| CONNOLLY CONSULTING | 1 | 2007 |
| YAMAHA MOTOR CORPORATION | 1 | 2007 |
H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); S.771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R.1316-The Prescription Drug Price Transparency Act; HHS-OIG rule RIN -936-AAO8 entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017. S. 2553-Know the Lowest Price Act.
Prescription Drug Price Transparency Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); S.771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R.1316-The Prescription Drug Price Transparency Act; HHS-OIG rule RIN -936-AAO8 entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
Prescription Drug Price Transparency Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017. S. 2553-Know the Lowest Price Act.
Prescription Drug Price Transparency Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.
Prescription Drug Price Transparency Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC);H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR);S. 2553-Know the Lowest Price Act;Proposed HHS-OIG rule RIN -936-AAO8 under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.;H.R. 6-SUPPORT for Patients and Communities Act relating to S.2460 & H.R. 3528 (Every Prescription Controlled Securely Act);
Consolidated Appropriations Act, 2018
Client: LUPIN PHARMACEUTICALS, INC · Firm: BROWN RUDNICK LLP
H.R. 1892-The Bipartisan Budget Act of 2018 relating to the sunset of biosimilars exclusion from the Medicare D discount program and REMS reform. H.R. 1625-Consolidated Appropriations Act of 2018 relating to REMS reform.
H.R. 1892-The Bipartisan Budget Act of 2018 & H.R. 1625-Consolidated Appropriations Act of 2018 relating to REMS reform.
Improving Access To Affordable Prescription Drugs Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); S.771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R.1316-The Prescription Drug Price Transparency Act; HHS-OIG rule RIN -936-AAO8 entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
Improving Access To Affordable Prescription Drugs Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to regulation of biosimilars; S. 771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).
H.R. 1892-The Bipartisan Budget Act of 2018 & H.R. 1625-Consolidated Appropriations Act of 2018 relating to REMS reform.
H.R. 1892-The Bipartisan Budget Act of 2018 relating to the sunset of biosimilars exclusion from the Medicare D discount program and REMS reform. H.R. 1625-Consolidated Appropriations Act of 2018 relating to REMS reform.
Bipartisan Budget Act of 2018
Client: HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) · Firm: BROWN RUDNICK LLP
H.R. 1892-The Bipartisan Budget Act of 2018
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price;
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017. S. 2553-Know the Lowest Price Act.
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act.
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act.
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to regulation of biosimilars; S. 771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).H.R.6-SUPPORT for Patients and Communities Act.
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; S. 2476-Expanding Access to Low Cost Generic Drugs Act; Issues relating to generic drug pricing; Public Law 115-52 (The FDA Reauthorization Act of 2017)section 808 relating to the Competitive Generic Therapy ("CGT") designation.
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R.6641-The COST Act.
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES);HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act; Issues relating to generic drug pricing.
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act.
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. H.R. 5311 & S.2456-CARA 2.0 Act of 2018
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act.
H.R.302-Federal Aviation Administration Reauthorization Act relating to lithium batteries.
Every Prescription Conveyed Securely Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).H.R.6-SUPPORT for Patients and Communities Act.
Every Prescription Conveyed Securely Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC);H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR);S. 2553-Know the Lowest Price Act;Proposed HHS-OIG rule RIN -936-AAO8 under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.;H.R. 6-SUPPORT for Patients and Communities Act relating to S.2460 & H.R. 3528 (Every Prescription Controlled Securely Act);
Every Prescription Conveyed Securely Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to regulation of biosimilars; S. 771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).
To amend the Controlled Substances Act to clarify the process for denying, revoking, or suspending a registration to manufacture, distribute, or dispense a controlled substance, and for other purposes.
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; H.R. 5267 relating to DEA controlled substances registration; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion.
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. H.R. 5311 & S.2456-CARA 2.0 Act of 2018
H.R. 5311 & S. 2456-CARA 2.0 Act of 2018 relating to pain management.
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.
H.R. 1316-The Prescription Drug Price Transparency Act (MAC);H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR);S. 2553-Know the Lowest Price Act;Proposed HHS-OIG rule RIN -936-AAO8 under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.;H.R. 6-SUPPORT for Patients and Communities Act relating to S.2460 & H.R. 3528 (Every Prescription Controlled Securely Act);
H.R.6-SUPPORT for Patients and Communities Act relating to alternative medical technologies to treat chronic pain.
SUPPORT for Patients and Communities Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
H.R.6-SUPPORT for Patients and Communities Act relating to S.2838-Using Data to Prevent Opioid Diversion Act & S.2837-The Preventing Drug Diversion Act; S.2852 & H.R. 6378-Pandemic All-Hazards Preparedness Act.
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).H.R.6-SUPPORT for Patients and Communities Act.
SUPPORT for Patients and Communities Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
H.R.6-SUPPORT for Patients and Communities Act; S.2838-Using Data to Prevent Opioid Diversion Act; S.2837-The Preventing Drug Diversion Act.
Stopping EPA Overreach Act of 2017
Client: HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) · Firm: BROWN RUDNICK LLP
S. 2852 & H.R.637/H.R.7328-The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
H.R.6-SUPPORT for Patients and Communities Act relating to S.2838-Using Data to Prevent Opioid Diversion Act & S.2837-The Preventing Drug Diversion Act; S.2852 & H.R. 6378-Pandemic All-Hazards Preparedness Act.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
Issues related to the HHS RFI on the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; S.2852 & H.R. 6378-Pandemic All-Hazards Preparedness Act.
True Cost-sharing Of Seniors' drugs Transparency Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R.6641-The COST Act.
Shared Accountability for Improved Patient Outcomes Act of 2018
Client: MEDTRONIC INC · Firm: BROWN RUDNICK LLP
H.R. 7177-Shared Accountability for Improved Patient Outcomes Act of 2018; Draft Senate legislation to amend the Social Security Act to promote value-based arrangements; Issues relating to anti-kickback and physician self-referral prohibitions relating to healthcare value-based arrangements.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) · Firm: BROWN RUDNICK LLP
S. 2852 & H.R.637/H.R.7328-The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017. S. 2553-Know the Lowest Price Act.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price;
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price.
Foreign Investment Risk Review Modernization Act of 2018
Client: MEDTRONIC INC · Firm: BROWN RUDNICK LLP
S.2098-The Foreign Investment Risk Review Modernization Act relating to CFIUS.
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. H.R. 5311 & S.2456-CARA 2.0 Act of 2018
H.R. 5311 & S. 2456-CARA 2.0 Act of 2018 relating to pain management.
H.R. 1316-The Prescription Drug Price Transparency Act (MAC);H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR);S. 2553-Know the Lowest Price Act;Proposed HHS-OIG rule RIN -936-AAO8 under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.;H.R. 6-SUPPORT for Patients and Communities Act relating to S.2460 & H.R. 3528 (Every Prescription Controlled Securely Act);
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to regulation of biosimilars; S. 771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).H.R.6-SUPPORT for Patients and Communities Act.
Expanding Access to Low Cost Generic Drugs Act
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act.
Expanding Access to Low Cost Generic Drugs Act
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; S. 2476-Expanding Access to Low Cost Generic Drugs Act; Issues relating to generic drug pricing; Public Law 115-52 (The FDA Reauthorization Act of 2017)section 808 relating to the Competitive Generic Therapy ("CGT") designation.
Expanding Access to Low Cost Generic Drugs Act
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act; Issues relating to generic drug pricing.
Expanding Access to Low Cost Generic Drugs Act
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act.
H.R. 1316-The Prescription Drug Price Transparency Act (MAC);H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR);S. 2553-Know the Lowest Price Act;Proposed HHS-OIG rule RIN -936-AAO8 under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.;H.R. 6-SUPPORT for Patients and Communities Act relating to S.2460 & H.R. 3528 (Every Prescription Controlled Securely Act);
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017. S. 2553-Know the Lowest Price Act.
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
Opioid Crisis Response Act of 2018
Client: HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) · Firm: BROWN RUDNICK LLP
S. 2852-The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;S. 2680-The Opioid Crisis Response Act of 2018.
Opioid Crisis Response Act of 2018
Client: HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) · Firm: BROWN RUDNICK LLP
S. 2852-The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;S. 2680-The Opioid Crisis Response Act of 2018.
Preventing Drug Diversion Act of 2018
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
H.R.6-SUPPORT for Patients and Communities Act relating to S.2838-Using Data to Prevent Opioid Diversion Act & S.2837-The Preventing Drug Diversion Act; S.2852 & H.R. 6378-Pandemic All-Hazards Preparedness Act.
Preventing Drug Diversion Act of 2018
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
H.R.6-SUPPORT for Patients and Communities Act; S.2838-Using Data to Prevent Opioid Diversion Act; S.2837-The Preventing Drug Diversion Act.
Using Data to Prevent Opioid Diversion Act of 2018
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
H.R.6-SUPPORT for Patients and Communities Act; S.2838-Using Data to Prevent Opioid Diversion Act; S.2837-The Preventing Drug Diversion Act.
Using Data to Prevent Opioid Diversion Act of 2018
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
H.R.6-SUPPORT for Patients and Communities Act relating to S.2838-Using Data to Prevent Opioid Diversion Act & S.2837-The Preventing Drug Diversion Act; S.2852 & H.R. 6378-Pandemic All-Hazards Preparedness Act.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) · Firm: BROWN RUDNICK LLP
S. 2852-The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;S. 2680-The Opioid Crisis Response Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
H.R.6-SUPPORT for Patients and Communities Act relating to S.2838-Using Data to Prevent Opioid Diversion Act & S.2837-The Preventing Drug Diversion Act; S.2852 & H.R. 6378-Pandemic All-Hazards Preparedness Act.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) · Firm: BROWN RUDNICK LLP
S. 2852-The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;S. 2680-The Opioid Crisis Response Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) · Firm: BROWN RUDNICK LLP
S. 2852 & H.R.637/H.R.7328-The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
Issues related to the HHS RFI on the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; S.2852 & H.R. 6378-Pandemic All-Hazards Preparedness Act.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC);H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR);S. 2553-Know the Lowest Price Act;Proposed HHS-OIG rule RIN -936-AAO8 under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.;H.R. 6-SUPPORT for Patients and Communities Act relating to S.2460 & H.R. 3528 (Every Prescription Controlled Securely Act);
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); S.771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R.1316-The Prescription Drug Price Transparency Act; HHS-OIG rule RIN -936-AAO8 entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017. S. 2553-Know the Lowest Price Act.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.
Affordable and Safe Prescription Drug Importation Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; H.R. 5267 relating to DEA controlled substances registration; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion.
Affordable and Safe Prescription Drug Importation Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
Public Law 115-271-SUPPORT for Patients and Communities Act; S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act.
Affordable and Safe Prescription Drug Importation Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion.
Affordable and Safe Prescription Drug Importation Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC · Firm: BROWN RUDNICK LLP
S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017. S. 2553-Know the Lowest Price Act.
HHS-OIG rule RIN-936-AAO8,Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2019 · first_quarter · 1T
Issues relating to affordable pharmaceutical pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDTRONIC INC via BROWN RUDNICK LLP
2019 · first_quarter · 1T
issues relating to Medicare value-based health care
issues relating to non-pharmacology pain treatment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2019 · first_quarter · 1T
Public Law 115-52, Section 808, relating to the Competitive Generic Therapy designation; President's FY19 budget proposal relating to generic drug 180-Day exclusivity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2018 · fourth_quarter · Q4
H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); S.771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R.1316-The Prescription Drug Price Transparency Act; HHS-OIG rule RIN -936-AAO8 entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES);HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2018 · fourth_quarter · Q4
H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; S. 2476-Expanding Access to Low Cost Generic Drugs Act; Issues relating to generic drug pricing; Public Law 115-52 (The FDA Reauthorization Act of 2017)section 808 relating to the Competitive Generic Therapy ("CGT") designation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2018 · fourth_quarter · Q4
Public Law 115-271-SUPPORT for Patients and Communities Act; S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act.
Issues related to the HHS RFI on the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; S.2852 & H.R. 6378-Pandemic All-Hazards Preparedness Act.
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price.
MEDTRONIC INC via BROWN RUDNICK LLP
2018 · fourth_quarter · Q4
issues related to Section 301 tariffs.
H.R. 7177-Shared Accountability for Improved Patient Outcomes Act of 2018; Draft Senate legislation to amend the Social Security Act to promote value-based arrangements; Issues relating to anti-kickback and physician self-referral prohibitions relating to healthcare value-based arrangements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LUPIN PHARMACEUTICALS, INC via BROWN RUDNICK LLP
2018 · fourth_quarter · Q4
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) via BROWN RUDNICK LLP
2018 · fourth_quarter · Q4
S. 2852 & H.R.637/H.R.7328-The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.
Diagnostic Accuracy & Innovation Act (DAIA) Discussion Draft; The Verifying Accurate Leading-edge IVCT Development(VALID) Act of 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2018 · third_quarter · Q3
H.R.6-SUPPORT for Patients and Communities Act relating to S.2838-Using Data to Prevent Opioid Diversion Act & S.2837-The Preventing Drug Diversion Act; S.2852 & H.R. 6378-Pandemic All-Hazards Preparedness Act.
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price.
S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDTRONIC INC via BROWN RUDNICK LLP
2018 · third_quarter · Q3
H.R.302-Federal Aviation Administration Reauthorization Act relating to lithium batteries.
Issues relating to Medicare value-based payment arrangements and modernization of fraud and abuse laws.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2018 · third_quarter · Q3
H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act; Issues relating to generic drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2018 · third_quarter · Q3
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R.6641-The COST Act.
H.R. 1316-The Prescription Drug Price Transparency Act (MAC);H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR);S. 2553-Know the Lowest Price Act;Proposed HHS-OIG rule RIN -936-AAO8 under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.;H.R. 6-SUPPORT for Patients and Communities Act relating to S.2460 & H.R. 3528 (Every Prescription Controlled Securely Act);
LUPIN PHARMACEUTICALS, INC via BROWN RUDNICK LLP
2018 · third_quarter · Q3
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) via BROWN RUDNICK LLP
2018 · third_quarter · Q3
Diagnostic Accuracy & Innovation Act (DAIA)Discussion Draft
S. 2852-The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;S. 2680-The Opioid Crisis Response Act of 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDTRONIC INC via BROWN RUDNICK LLP
2018 · second_quarter · Q2
Issues relating to the CDC Opioids Prescribing Checklist.
Issues relating to Medicare value-based health care and modernization of fraud and abuse laws.
Federal Aviation Administration Reauthorization Act relating to lithium batteries.
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2018 · second_quarter · Q2
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).H.R.6-SUPPORT for Patients and Communities Act.
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2018 · second_quarter · Q2
H.R.6-SUPPORT for Patients and Communities Act; S.2838-Using Data to Prevent Opioid Diversion Act; S.2837-The Preventing Drug Diversion Act.
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price.
Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion.
LUPIN PHARMACEUTICALS, INC via BROWN RUDNICK LLP
2018 · second_quarter · Q2
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2018 · second_quarter · Q2
President's Fiscal Year 2019 Budget relating to 180-Day Exclusivity for Generic Drugs
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) via BROWN RUDNICK LLP
2018 · second_quarter · 2A
Diagnostic Accuracy & Innovation Act (DAIA)Discussion Draft
S. 2852-The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;S. 2680-The Opioid Crisis Response Act of 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2018 · first_quarter · Q1
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to regulation of biosimilars; S. 771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017. S. 2553-Know the Lowest Price Act.
LUPIN PHARMACEUTICALS, INC via BROWN RUDNICK LLP
2018 · first_quarter · Q1
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 1892-The Bipartisan Budget Act of 2018 relating to the sunset of biosimilars exclusion from the Medicare D discount program and REMS reform. H.R. 1625-Consolidated Appropriations Act of 2018 relating to REMS reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDTRONIC INC via BROWN RUDNICK LLP
2018 · first_quarter · Q1
Issues relating to Medicare value-based health care and continuous glucose monitoring.
H.R. 5311 & S. 2456-CARA 2.0 Act of 2018 relating to pain management.
Issues relating to the CDC Opioids Prescribing Checklist.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2018 · first_quarter · Q1
Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; H.R. 5267 relating to DEA controlled substances registration; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion.
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price;
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2018 · first_quarter · Q1
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act.
H.R. 1892-The Bipartisan Budget Act of 2018 & H.R. 1625-Consolidated Appropriations Act of 2018 relating to REMS reform.
Issues relating to the USPTO inter partes review proceeding.
HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) via BROWN RUDNICK LLP
2018 · first_quarter · Q1
Pandemic and All-Hazards Preparedness Reauthorization Act
H.R. 1892-The Bipartisan Budget Act of 2018
Draft Diagnostic Accuracy & Innovation Act (DAIA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2018 · first_quarter · Q1
H.R.2212 & S.974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. H.R. 5311 & S.2456-CARA 2.0 Act of 2018
Bipartisan Budget Act of 2018; Consolidated Appropriations Act of 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOOPER LUNDY & BOOKMAN P C (OBO ROCHE DIAGNOSTICS) via BROWN RUDNICK LLP
2018 · first_quarter · RR
FDA diagnostics reform
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2017 · fourth_quarter · Q4
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to regulation of biosimilars; S. 771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R. 3528-Every Prescription Conveyed Securely Act (e-prescribing).Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums.
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2017 · fourth_quarter · Q4
Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion;
H.Con.Res. 71 relating to drug importation
LIFO Accounting Methodology (H.R.1)
APOTEX CORPORATION via BROWN RUDNICK LLP
2017 · fourth_quarter · 4A
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2017 · fourth_quarter · 4A
2017 China Trade Mission
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2017 · fourth_quarter · Q4
Issues relating to inter parte review challenges.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDTRONIC INC via BROWN RUDNICK LLP
2017 · fourth_quarter · Q4
Federal Aviation Administration Reauthorization Act
Issues related to pain management
Issues relating to Medicare value-based health care and continuous glucose monitoring.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2017 · fourth_quarter · Q4
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2017 · fourth_quarter · 4T
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage;tax issues related to ACA repeal.H.R. 1628-American Health Care Act of 2017, provisions related to the business of dental benefits;H.R.4620-Protecting Families and Small Businesses Act of 2017 as related to the Fee on Health Insurance Providers on dental plans.
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R.1606-DOC Access Act; H.R.1628-The American Health Care Act of 2017;Senate proposals to repeal the Affordable Care Act;The Bipartisan Health Care Stabilization Act of 2017;H.R.4620-Protecting Families and Small Businesses Act of 2017 as related to the Fee on Health Insurance Providers on dental plans.
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2017 · fourth_quarter · 4T
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017;S. 1914 - Protecting Access to Diabetes Supplies Act of 2017;Yet to be introduced House proposal for a regulatory framework for in-vitro clinical tests.
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017;S. 1914 - Protecting Access to Diabetes Supplies Act of 2017;Yet to be introduced House and Senate proposal for a regulatory framework for in-vitro clinical tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2017 · third_quarter · Q3
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R. 1606 - DOC Access Act; H.R. 1628, the American Health Care Act of 2017, Senate proposals to repeal the Affordable Care Act.
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; H.R. 1628, the American Health Care Act of 2017, provisions related to the business of dental benefits. Yet to be introduced Senate legislation related to repeal of the Affordable Care Act, provisions related to the business of dental benefits.
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2017 · third_quarter · Q3
Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion;
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price;
LIFO Accounting Methodology
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2017 · third_quarter · Q3
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017; yet to be introduced Senate proposal on Medicare competitive bidding related to diabetes testing supplies; Yet to be introduced House proposal for a regulatory framework for in-vitro clinical tests; Yet to be introduced Senate proposal for a regulatory framework for in-vitro clinical tests.
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017; yet to be introduced Senate proposal on Medicare competitive bidding related to diabetes testing supplies; Yet to be introduced House proposal for a regulatory framework for in-vitro clinical tests; Yet to be introduced Senate proposal for a regulatory framework for in-vitro clinical tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2017 · third_quarter · Q3
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2999-Patients' Access to Treatments Act of 2017 (specialty tier cosharing); Issues relating to regulation of biosimilars;
S.469-The Affordable and Safe Prescription Drug Importation Act.
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
MEDTRONIC INC via BROWN RUDNICK LLP
2017 · third_quarter · Q3
HR 2430 & S. 934-FDA Reauthorization Act of 2017.
Issues relating to Medicare value-based health care and continuous glucose monitoring.
Federal Aviation Administration Reauthorization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2017 · third_quarter · Q3
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2017 · third_quarter · Q3
Issues relating to inter parte review challenges.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2017 · second_quarter · Q2
Issues relating to inter parte review challenges.
H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2051 - The FAST Generics Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2017 · second_quarter · Q2
H.R. 2430 & S. 934-FDA Reauthorization Act of 2017.
LIFO Accounting Methodology
S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145: The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion.
LUPIN PHARMACEUTICALS, INC via BROWN RUDNICK LLP
2017 · second_quarter · 2A
border adjustability tax
H.R. 2051 - The FAST Generics Act; H.R. 2212 - CREATES Act of 2017; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 2430 - FDA Reauthorization Act of 2017.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2017 · second_quarter · Q2
Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; Yet to be introduced House proposal on Medicare competitive bidding proposal related to diabetes supplies; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; Yet to be introduced House proposal on Medicare competitive bidding proposal related to diabetes supplies; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2017 · second_quarter · Q2
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R. 1606 - DOC Access Act
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; H.R. 1628, the American Health Care Act of 2017, provisions related to the business of dental benefits. Yet to be introduced Senate legislation related to repeal of the Affordable Care Act, provisions related to the business of dental benefits.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2017 · second_quarter · Q2
H.R. 2051 - The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2017 · second_quarter · Q2
S.469-The Affordable and Safe Prescription Drug Importation Act
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; S.1003 relating to drug compendia & Medicaid drug payment. H.R. 1939 & S.1044-Ensuring Seniors Access to Local Pharmacies Act of 2017.
MEDTRONIC INC via BROWN RUDNICK LLP
2017 · second_quarter · Q2
H.R. 1628- The American Health Care Act of 2017 and Senate Better Care Reconciliation Act of 2017 amendment; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; issues relating to medical device cybersecurity
Issues relating to value-based health care
Federal Aviation Administration Reauthorization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LUPIN PHARMACEUTICALS, INC via BROWN RUDNICK LLP
2017 · second_quarter · RR
H.R. 2051 - The FAST Generics Act; HR 749 - The Lower Drug Costs Through Competition Act; border adjustability tax
H.R. 2051 - The FAST Generics Act; HR 749 - The Lower Drug Costs Through Competition Act; border adjustability tax
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2017 · first_quarter · Q1
HR 749 - The Lower Drug Costs Through Competition Act; H.R. 2051 - The FAST Generics Act; S. 297-Increasing Competition in Pharmaceuticals Act; S.469-The Affordable and Safe Prescription Drug Importation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2017 · first_quarter · Q1
HR 749 - The Lower Drug Costs Through Competition Act
Issues relating to reauthorization of the Generic Drug User Fee Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2017 · first_quarter · Q1
S.469-The Affordable and Safe Prescription Drug Importation Act
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; Issues relating to Medicare Part D cash price disclosure
HR 1628-American Health Care Act of 2017; H.R. 2051 - The FAST Generics Act; HR 749 - The Lower Drug Costs Through Competition Act; Reauthorization of the Generic Durg User Fee Act; Issues relating to biosimilars and speciality pharmacy; HR 1776 & S. 771- Improving Access to Affordable Prescription Drugs Act
MEDTRONIC INC via BROWN RUDNICK LLP
2017 · first_quarter · Q1
Issues relating to chronic care and value-based health care
H.R. 1628- The American Health Care Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2017 · first_quarter · Q1
S.Con.Res.3-Congressional Budget FY 2017 relating to drug importation
HR 5-Regulatory Accountability Act of 2017
Issues relating to ASP and Part B prescription drug reimbursement
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2017 · first_quarter · Q1
Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; Yet to be introduced House proposal on Medicare competitive bidding proposal related to diabetes supplies; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; Yet to be introduced House proposal on Medicare competitive bidding proposal related to diabetes supplies; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2017 · first_quarter · Q1
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R. 1606 - DOC Access Act
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies; H.R.1726 - Access to Quality Diabetes Education Act of 2015
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; H.R. 3463, Aligning Children's Dental Coverage Act" ; S. 3244, Aligning Childrens Dental Coverage Act
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
Issues relating to biosimilars and Part D preferred pharmacy networks; CMS Proposed Guidance on Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions; H.R.4062 - Protecting Seniors Access to Proper Care Act of 2015; HR 5951-Improving Transparency and Accuracy in Medicare Part D Spending Act.
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 34 - Century Cures Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; S.3056-The CREATES Act; HR 34-21st Century Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
LIFO Accounting Methodology
Issues relating to ASP and Part B prescription drug reimbursement
Issues relating to prescription drug abuse (H.R. 471, S.483, S. 524, H.R. 953, H.R. 4641) and pharmaceutical market value
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDTRONIC INC via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
H.R. 1427 & S.804-Medicare CGM Access Act of 2015
Issues relating to chronic care and value-based health care; HR 34 - 21st Century Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
HRC: S.3056-CREATES; HR 34 - 21st Century Cures Act.
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015; H.R. 9 - The Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2016 · third_quarter · Q3
Issues relating to biosimilars and Part D preferred pharmacy networks; CMS Proposed Guidance on Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions; H.R.4062 - Protecting Seniors Access to Proper Care Act of 2015; HR 5951-Improving Transparency and Accuracy in Medicare Part D Spending Act.
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 4981 -The Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4599 - Reducing Unused Medications Act of 2016; S. 2256 - Co-Prescribing Saves Lives; HR 3680 - Co-Prescribing to Reduce Overdoses Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2016 · third_quarter · Q3
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; S.3056-The CREATES Act
HR 4981 -Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4976 - Opioid Review Modernization Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2016 · third_quarter · Q3
LIFO Accounting Methodology
Issues relating to ASP and Part B prescription drug reimbursement
Issues relating to prescription drug abuse (H.R. 471, S.483, S. 524, H.R. 953, H.R. 4641) and pharmaceutical market value
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDTRONIC INC via BROWN RUDNICK LLP
2016 · third_quarter · Q3
Issues relating to chronic care and value-based health care
Issues relating to state taxation
S. 2658 - The Federal Aviation Administration Reauthorization Act of 2016; HR 636 - America's Small Business Tax Relief Act of 2015 relating to air shipment of lithium batteries
APOTEX CORPORATION via BROWN RUDNICK LLP
2016 · third_quarter · Q3
HRC: S.3056-CREATES
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015; H.R. 9 - The Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2016 · third_quarter · 3A
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies; H.R.1726 - Access to Quality Diabetes Education Act of 2015
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2016 · third_quarter · Q3
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; H.R. 3463, Aligning Children's Dental Coverage Act" ; S. 3244, Aligning Childrens Dental Coverage Act
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2016 · third_quarter · Q3
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2016 · second_quarter · Q2
H.R. 5122 relating to the Medicare Part B prescription drug demonstration
S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 524 Comprehensive Addiction and Recovery Act (CARA); H.R. 5046- Comprehensive Opioid Abuse Reduction Act of 2016: H.R. 4641 relating to the establishment of an inter-agency task force on best practices for pain management and prescribing
General issues relating to LIFO accounting methodology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2016 · second_quarter · Q2
S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 524 Comprehensive Addiction and Recovery Act (CARA); H.R. 5046- Comprehensive Opioid Abuse Reduction Act of 2016: H.R. 4641 relating to the establishment of an inter-agency task force on best practices for pain management and prescribing
H.R. 5122 relating to the Medicare Part B prescription drug demonstration
General issues relating to LIFO accounting methodology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2016 · second_quarter · Q2
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015; H.R. 9 - The Innovation Act
S.131 - The FAIR Generics Act; S. 2615 - Increasing Competition in Pharmaceutical Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2016 · second_quarter · Q2
HR 4981 -Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4976 - Opioid Review Modernization Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; S.3056-The CREATES Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2016 · second_quarter · Q2
Federal policy relating to pharmaceutical pricing and FDA application review protocols
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2016 · second_quarter · Q2
Issues relating to biosimilars and Part D preferred pharmacy networks; CMS Proposed Guidance on Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 4981 -The Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4599 - Reducing Unused Medications Act of 2016; S. 2256 - Co-Prescribing Saves Lives; HR 3680 - Co-Prescribing to Reduce Overdoses Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MEDTRONIC INC via BROWN RUDNICK LLP
2016 · second_quarter · Q2
S. 2658 - The Federal Aviation Administration Reauthorization Act of 2016; HR 636 - America's Small Business Tax Relief Act of 2015 relating to air shipment of lithium batteries
Issues relating to chronic care and value-based health care
HR 1427 & S 804 - Medicare CGM Access Act of 2015; HR 5210 - Patient Access to Durable Medical Equipment Act of 2016
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2016 · second_quarter · Q2
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2016 · second_quarter · Q2
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; H.R. 3463, "Aligning Children's Dental Coverage Act", yet to be introduced Senate companion bill to H.R. 3463
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
MEDTRONIC INC via BROWN RUDNICK LLP
2016 · first_quarter · Q1
S. 2658 - The Federal Aviation Administration Reauthorization Act of 2016; HR 636 - America's Small Business Tax Relief Act of 2015 relating to air shipment of lithium batteries.
HR 1427 & S 804 - Medicare CGM Access Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Issues relating to GDUFA implementation and pharmaceutical pricing; S.131 - The FAIR Generics Act; S. 2615 - Increasing Competition in Pharmaceutical Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYDUS PHARMACEUTICALS USA INC. via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Federal policy relating to pharmaceutical pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Federal policy relating to pharmaceutical pricing and FDA application review protocols
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2016 · first_quarter · Q1
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; Innovations for Healthier Americans
Federal policy relating to abuse deterrent drug development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Federal policy relating to prescription drug abuse and preferred pharmacy networks
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244, the MAC Transparency Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC via BROWN RUDNICK LLP
2016 · first_quarter · Q1
General issues relating to LIFO accounting methodology
H.R. 471 & S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 524 relating to the prevention and treatment of opioid addiction
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; S. 1101 Medical Electronic Data Technology Enhancement for consumers Health Act; H.R. 6 "21st Century Cures Act".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MIRACA LIFE SCIENCES via BROWN RUDNICK LLP
2016 · first_quarter · 1T
Proposals related to anatomic pathology and the in-office ancillary services exception to the Ethics in Patient Referrals Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MEDTRONIC INC via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
HR 1427 & S 804 Medicare CGM Access Act of 2015
Issues relating to the negotiation of the Trans-Pacific Partnership Agreements and competitiveness of the U.S. healthcare sector in international markets.
Federal policy relating to the air shipment of lithium batteries
MIRACA LIFE SCIENCES via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
Proposals related to anatomic pathology and the in-office ancillary services exception to the Ethics in Patient Referrals Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit.
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.2098-The Foreign Investment Risk Review Modernization Act relating to CFIUS.
H.R.6-SUPPORT for Patients and Communities Act relating to alternative medical technologies to treat chronic pain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
P.L. 114-74 section 602 relating to Medicaid additional rebate for generic drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.469-The Affordable and Safe Prescription Drug Importation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price;
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 2430 & S. 934-FDA Reauthorization Act of 2017.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.1304 & H.R. 1920 relating to customary prompt pay discounts from manufacturers to wholesalers from the average sales price
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFO Accounting Methodology
S.469-The Affordable and Safe Prescription Drug Importation Act; Implementation of Public Laws 114-145 and 113-54 (DSCSA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 1427 & S.804-Medicare CGM Access Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
International tax issues including the taxation of foreign earnings and territorial tax reform; H.R.160 - Protect Medical Innovation Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE